Patients and clinicians should verify current federal and state requirements and consult qualified medical and pharmacy professionals before making treatment decisions.
available only through 503A compounding pharmacies under physician supervision Typical research dose range / 200-800 mcg/day subcutaneously, cycled 4-8 weeks Known lethal dose (LD50) / Not established in any species studied to date Rodent acute toxicity ceiling / No mortality observed at doses exceeding 10 mg/kg intraperitoneally Most reported excess-dose symptoms / Nausea, lightheadedness, flushing, injection-site irritation Organ toxicity at supratherapeutic doses / Not demonstrated in published preclinical literature Antidote availability / No specific antidote exists
Anyone over 18 is a reasonable candidate, since the bodys natural production of GHK-Cu starts declining in early adulthood
Extensive docking studies were carried out to investigate Epitalons interaction with various histone proteins, including H1/1, H1/3, H1/6, H2b, H3, and H4
As a growth hormone-releasing hormone (GHRH) analog, sermorelin stimulates t